HOW GOOD ELDERLY RHEUMATOID ARTHRITIS PATIENTS RESPOND AT FIRST YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL?

被引：0
|
作者：
Torrente-Segarra, V. [1 ]
Prada, M. Fernandez [2 ]
Exposito, R. [3 ]
Punal, N. Garrido [4 ]
Sanchez-Andrade, A. [5 ]
Lamua-Riazuelo, J. R. [6 ]
Olive, A. [7 ]
Tovar, J. V. [8 ]
机构：
[1] Hosp Gen Hospitalet Moises Bragg, Rheumatol, Lhospitalet De Llobregat, Spain
[2] Hosp Univ Guadalajara, Guadalajara, Spain
[3] Hosp Comarcal Laredo, Laredo, Spain
[4] Hosp Univ Virgen Rocio, Seville, Spain
[5] Complejo Hosp Univ Lucus Augusti, Alicante, Spain
[6] Hosp Univ Henares, Alcala De Henares, Spain
[7] Hosp Germans Tries & Pujol, Badalona, Spain
[8] Hosp Gen Univ Elche, Elche, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1727
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0208
引用
收藏
页码：964 / 965
页数：2
相关论文
共 50 条
  • [31] SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)
    van Vollenhoven, Raymond
    Smolen, Josef
    Schiff, Michael
    Fleischmann, Roy
    Combe, Bernard
    Goel, Niti
    Desai, Chintu
    Curtis, Jeffery
    Keystone, Edward
    Emery, Paul
    Choy, Ernest
    RHEUMATOLOGY, 2010, 49 : I102 - I103
  • [32] Patients with rheumatoid arthritis achieve a rapid response when treated with certolizumab pegol irrespective of background treatment
    Fleischmann, Roy M.
    Keystone, Edward C.
    Luijtens, Kristel
    Furst, Daniel E.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S528 - S528
  • [33] Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
    Ruiz Garcia, Vicente
    Jobanputra, Paresh
    Burls, Amanda
    Cabello, Juan B.
    Vela Casasempere, Paloma
    Bort-Marti, Sylvia
    Kynaston-Pearson, Francis J. B.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (09):
  • [34] Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Okamoto, Tadao
    Wada, Yumiko
    Shoji, Toshiharu
    Miyasaka, Nobuyuki
    Koike, Takao
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S990 - S990
  • [35] CERTOLIZUMAB PEGOL EXPOSURE IN RHEUMATOID ARTHRITIS PREGNANCIES: A CASE SERIES
    Meroni, M.
    Pizzorni, C.
    Paolino, S.
    Gerbaldo, D.
    Gustavino, C.
    Seriolo, B.
    Cutolo, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 990 - 990
  • [36] Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
    Hannech, Emna
    Boussaid, Soumaya
    Rekik, Sonia
    Jemmali, Samia
    Ajlani, Houda
    Cheour, Elhem
    Sahli, Hela
    Elleuch, Mohamed
    CLINICAL CASE REPORTS, 2021, 9 (06):
  • [37] Certolizumab Pegol A Review of Its Use in the Management of Rheumatoid Arthritis
    Deeks, Emma D.
    DRUGS, 2013, 73 (01) : 75 - 97
  • [38] Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
    Ruiz Garcia, Vicente
    Jobanputra, Paresh
    Burls, Amanda
    Cabello, Juan B.
    Galvez Munoz, Jose G.
    Saiz Cuenca, Encarnacion S. C.
    Fry-Smith, Anne
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02):
  • [39] Certolizumab Pegol Therapy for Rheumatoid Arthritis-Associated Scleritis
    Tlucek, Paul S.
    Stone, Donald U.
    CORNEA, 2012, 31 (01) : 90 - 91
  • [40] Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
    Mease, Philip J.
    RHEUMATOLOGY, 2011, 50 (02) : 261 - 270
12345